High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Hayette, Sandrine ^a,b   Thomas, Xavier ^a   Jallades, Laurent ^a,b   Chabane, Kaddour ^a,b   Charlot, Carole ^a   Tigaud, Isabelle ^a   Gazzo, Sophie ^a,b   Morisset, Stéphane ^a   Cornillet Lefebvre, Pascale ^c   Plesa, Adriana ^a   Huet, Sarah ^a,b   Renneville, Aline ^d   Salles, Gilles ^a,b   Nicolini, Franck Emmanuel ^a   Magaud, Jean Pierre ^a,b   Michallet, Mauricette ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR HOXA9; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DNA METHYLATION; DNMT3A GENE; DNMT3B GENE; EVENT FREE SURVIVAL; EVI1 GENE; FEMALE; FLT3ITD GENE; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HOXA9 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MLL GENE; NPM1 GENE; OVERALL SURVIVAL; PREDICTION; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; DISEASE-FREE SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; SEQUENCE ALIGNMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84870864252     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051527     Document Type: Article

References (46)

1. Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, et al. (2011) Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 117: 234-241.
2. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, et al. (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17: 13-27.
3. Razin A, Riggs AD, (1980) DNA methylation and gene function. Science 210: 604-610.
4. Robertson KD, (2001) DNA methylation, methyltransferases, and cancer. Oncogene 20: 3139-3155.
5. Arand J, Spieler D, Karius T, Branco MR, Meilinger D, et al. (2012) In Vivo Control of CpG and Non-CpG DNA Methylation by DNA Methyltransferases. PLoS Genet 8: e1002750.
6. Okano M, Bell DW, Haber DA, Li E, (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257.
7. Chen T, Tsujimoto N, Li E, (2004) The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at pericentric heterochromatin. Mol Cell Biol 24: 9048-9058.
8. Kaneda M, Okano M, Hata K, Sado T, Tsujimoto N, et al. (2004) Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature 429: 900-903.
9. Ostler KR, Davis EM, Payne SL, Gosalia BB, Exposito-Cespedes J, et al. (2007) Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene 26: 5553-5563.
10. Van Emburgh BO, Robertson KD, (2011) Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants. Nucleic Acids Res 39: 4984-5002.
11. Jones PA, Baylin SB, (2007) The epigenomics of cancer. Cell 128: 683-692.
12. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
13. Ostler KR, Yang Q, Looney TJ, Zhang L, Vasanthakumar A, et al. (2012) Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation, and Alters DNA Methylation in Human Neuroblastoma. Cancer Res 72: 4714-4723.
14. Shah MY, Vasanthakumar A, Barnes NY, Figueroa ME, Kamp A, et al. (2010) DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res 70: 5840-5850.
15. Nucifora G, Laricchia-Robbio L, Senyuk V, (2006) EVI1 and hematopoietic disorders: history and perspectives. Gene 368: 1-11.
16. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, et al. (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111: 4329-4337.
17. Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, et al. (2010) High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 28: 2101-2107.
18. Wieser R, (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396: 346-357.
19. Senyuk V, Premanand K, Xu P, Qian Z, Nucifora G, (2011) The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. PLoS One 6: e20793.
20. Walter MJ, Ding L, Shen D, Shao J, Grillot M, et al. (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25: 1153-1158.
21. Thol F, Winschel C, Ludeking A, Yun H, Friesen I, et al. (2011) Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 96: 1870-1873.
22. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, et al. (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424-2433.
23. Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, et al. (2012) Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia: Epub ahead of print.
24. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, et al. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29: 2889-2896.
25. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, et al. (2012) Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 119: 5824-5831.
26. Wang J, Walsh G, Liu DD, Lee JJ, Mao L, (2006) Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. Cancer Res 66: 8361-8366.
27. Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, et al. (2010) DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas. Cancer Sci 101: 1722-1730.
28. Zhang JJ, Zhu Y, Zhu Y, Wu JL, Liang WB, et al. (2012) Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma. Clin Transl Oncol 14: 116-124.
29. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33: 451-458.
30. Arber DA Brunning RD, Le Beau MM, Falini B (2008) Acute myeloid leukemia with recurrent genetic abnormalities In: Swerdlow SH, Harris NE, Pileri SA, Stein H, Thiele J, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues Lyon, France: International Agency for reseach on cancer Press (IARC). 110-123.
31. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, et al. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92: 2322-2333.
32. Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, et al. (2002) Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 16: 1699-1704.
33. Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, et al. (2005) Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 106: 3618-3620.
34. Poirel H, Rack K, Delabesse E, Radford-Weiss I, Troussard X, et al. (1996) Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood 87: 2496-2505.
35. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, et al. (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101: 837-845.
36. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, et al. (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia- a Europe Against Cancer program. Leukemia 17: 2318-2357.
37. Weisser M, Haferlach T, Schoch C, Hiddemann W, Schnittger S, (2004) The use of housekeeping genes for real-time PCR-based quantification of fusion gene transcripts in acute myeloid leukemia. Leukemia 18: 1551-1553.
38. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, et al. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642-4649.
39. Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, et al. (2011) Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 118: 1754-1762.
40. Larochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, et al. (2011) Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget 2: 850-861.
41. Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Bejar O, et al. (2011) Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 96: 1448-1456.
42. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, et al. (2011) Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117: 6304-6314.
43. Ehrlich M, (2003) The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol 109: 17-28.
44. Moarefi AH, Chedin F, (2011) ICF syndrome mutations cause a broad spectrum of biochemical defects in DNMT3B-mediated de novo DNA methylation. J Mol Biol 409: 758-772.
45. Hlady RA, Novakova S, Opavska J, Klinkebiel D, Peters SL, et al. (2012) Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J Clin Invest 122: 163-177.
46. Palakurthy RK, Wajapeyee N, Santra MK, Gazin C, Lin L, et al. (2009) Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol Cell 36: 219-230.